1106 CLINICAL AND MULTIMODAL IMAGING FOLLOW-UP OF PATIENTS WITH MYOPERICARDITIS FOLLOWING MRNA COVID-19 VACCINATION

Abstract Background Myopericarditis following coronavirus disease-2019 (COVID-19) vaccine is a described entity, but its evolution still unclear. Methods Patients with diagnosis of myopericarditis after mRNA COVID-19 represented our population. Clinical evaluation, laboratory tests and non-invasive cardiac were performed at baseline six months. Results Between January August 2021, we identified 7 patients vaccination. The median age was 29 years (IQR: 25.5–53.5 years) all males. time from administration to symptoms onset 5 days 4–7 days); five received BNT162b2, two mRNA-1273 only one patient developed first dose vaccine. most common presentation chest pain (100%) fatigue (71.4%). Left Ventricular Ejection Fraction (LVEF) preserved in 6 them while mildly reduced (median LVEF: 61.3% [IQR: 60–62.9%]). Late Gadolinium Enhancement detected Cardiac Magnetic Resonance the 42.9% cases. Treatment conservative for except one; pericardiocentesis necessary due massive pericardial effusion. At months follow-up asymptomatic normal troponin level, electrocardiogram echocardiogram confirming complete healing inflammatory process. Two booster without evidence myopericardial involvement. Conclusions associated COVID19 vaccination more frequent young males usually characterized by benign evolution.